Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Polymyxin B

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

48 API Suppliers, 15 USDMF, 8 CEP/COS, 2 JDMF, 2 EU WC, 2 KDMF, 19 NDC API, 25 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

15 Drugs in Development

15 Drugs in Development

FINISHED DOSAGE FORMULATIONS

181 FDF Dossiers, 97 FDA Orange Book, 38 Europe, 19 Canada, 8 South Africa, 19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

OINTMENT;OPHTHALMIC - 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM, OINTMENT;TOPICAL - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CREAM;TOPICAL - 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, OINTMENT;OPHTHALMIC - 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM, SOLUTION/DROPS;OPHTHALMIC - 10,000 UNITS/ML;EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 SPI Pharma, 5 DKSH, 8 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 Pfanstiehl, 9 Kirsch Pharma, 1 ACG Worldwide, 17 Actylis, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 24 BASF, 2 CD Formulation, 10 Corel Pharma Chem, 2 Esteem Industries, 3 Finar, 9 Gangwal Chemicals, 3 Ideal Cures, 11 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 4 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nippon Fine Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 5 Roquette, 17 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

40 Coating Systems & Additives, 39 Topical, 35 Solubilizers, 27 Thickeners and Stabilizers, 27 Parenteral, 20 Emulsifying Agents, 16 Controlled & Modified Release, 14 Film Formers & Plasticizers, 13 Surfactant & Foaming Agents, 8 Direct Compression, 8 Fillers, Diluents & Binders, 7 Granulation, 5 Rheology Modifiers, 5 Lubricants & Glidants, 5 Empty Capsules, 5 API Stability Enhancers, 4 Co-Processed Excipients, 4 Vegetarian Capsules, 3 Taste Masking, 3 Chewable & Orodispersible Aids, 2 Coloring Agents, 1 Disintegrants & Superdisintegrants

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 14 News #PharmaBuzz

GLOBAL SALES INFORMATION

26 US Medicaid Prescriptions, 1 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

33 APIs, 7 FDF Dossiers

REF. STANDARDS & IMPURITIES

1 EDQM, 2 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Xellia Pharmaceuticals ApS	Denmark	Novartis Korea Co., Ltd.	20210317-211-J-890(A)	Polymyxin B sulfate	2023-08-11	Xellia Pharmaceuticals ApS	Denmark	Dalslandsgade 11, 2300 Copenhagen S, Denmark
29/11/2025	Xellia Pharmaceuticals ApS	Denmark	Aging Life Science Co., Ltd.	20210317-211-J-890	Polymyxin B sulfate	2021-03-17	Xellia Pharmaceuticals ApS	Denmark	Dalslandsgade 11 2300 Copenhagen S.

Polymyxin B

Polymyxin B

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

48 API Suppliers

15 USDMF

8 CEP/COS

2 JDMF

2 EU WC

2 KDMF

19 NDC API

25 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

15 Drugs in Development

FINISHED DOSAGE FORMULATIONS

181 FDF Dossiers

97 FDA Orange Book

38 Europe

19 Canada

8 South Africa

19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

OINTMENT;OPHTHALMIC - 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

OINTMENT;TOPICAL - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CREAM;TOPICAL - 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

OINTMENT;OPHTHALMIC - 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

SOLUTION/DROPS;OPHTHALMIC - 10,000 UNITS/ML;EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 SPI Pharma

5 DKSH

8 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

1 Pfanstiehl

9 Kirsch Pharma

1 ACG Worldwide

17 Actylis

2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

24 BASF

2 CD Formulation

10 Corel Pharma Chem

2 Esteem Industries

3 Finar

9 Gangwal Chemicals

3 Ideal Cures

11 Kerry

3 Kima Chemical

6 Lonza Capsugel

4 Microlex e.U

2 Nanjing Bold Chemical

2 Nippon Fine Chemical

2 Nomisma Healthcare

1 Novo Excipients

1 Pluviaendo

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

5 Roquette

17 Seppic

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Sigachi Industries

2 The Dow Chemical Company

1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

40 Coating Systems & Additives

39 Topical

35 Solubilizers

27 Thickeners and Stabilizers

27 Parenteral

20 Emulsifying Agents

16 Controlled & Modified Release

14 Film Formers & Plasticizers

13 Surfactant & Foaming Agents

8 Direct Compression

8 Fillers, Diluents & Binders

7 Granulation

5 Rheology Modifiers

OINTMENT;TOPICAL - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CREAM;TOPICAL - 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION/DROPS;OPHTHALMIC - 10,000 UNITS/ML;EQ 1MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons